Neuroptika is a clinical stage biotechnology company formed in November 2018 as a spin out of Senju Pharmaceutical Co., Ltd, a privately held pharmaceutical company based in Osaka, Japan. Neuroptika is developing NRO-1, a novel therapeutic that protects and regenerates corneal nerves. NRO-1 has generated compelling data demonstrating accelerated nerve regeneration which led to the recovery of functional nerves and corneal sensitivity in animal studies.
A successful Phase 1 SAD/MAD clinical study is complete and we plan to initiate a Phase 2 clinical study for dry eye disease in the second half of 2019. While most dry eye treatments are focused on treating signs and symptoms, NRO-1 has the potential to become the first disease modifying regenerative treatment. NRO-1’s benefit is also being studied in other indications, including post-LASIK care, glaucoma and Leber's hereditary optic neuropathy. Our mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases.